Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment

Objectives: Although recognized for decades, little is known about the etiology, physiopathology, and prevention of persistent pulmonary hypertension of the newborn (PPHN). and its treatment remains a major challenge for neonatologists. In this review, the clinical features and physiopathology of th...

Full description

Bibliographic Details
Main Authors: Joaquim E.B. Cabral, Jaques Belik
Format: Article
Language:Portuguese
Published: Elsevier 2013-05-01
Series:Jornal de Pediatria (Versão em Português)
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2255553613000487
id doaj-a48102a9c55343fea334903481c8be4e
record_format Article
spelling doaj-a48102a9c55343fea334903481c8be4e2020-11-24T23:56:45ZporElsevierJornal de Pediatria (Versão em Português)2255-55362013-05-0189322624210.1016/j.jpedp.2012.11.002Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatmentJoaquim E.B. Cabral0Jaques Belik1Neonatologista. Hospital São Luiz, São Paulo, SP, BrasilNeonatologista. Professor of Pediatrics and Physiology, University of Toronto, The Hospital for Sick Children, Toronto, CanadáObjectives: Although recognized for decades, little is known about the etiology, physiopathology, and prevention of persistent pulmonary hypertension of the newborn (PPHN). and its treatment remains a major challenge for neonatologists. In this review, the clinical features and physiopathology of the syndrome will be addressed, as well as its general and specific treatments. Data source: A review was carried out in PubMed, Cochrane Library, and MRei consult databases, searching for articles related to the syndrome and published between 1995 and 2011. Data synthesis: Risk factors and the physiopathological mechanisms of the syndrome are discussed. The clinical picture depends on the different factors involved, which are probably related to the etiology and physiopathological mechanisms. In addition to the measures used to allow the decrease in pulmonary vascular resistance after birth, some cases will require pulmonary vasodilators. Although nitric oxide has proved effective, other vasodilators have been recently used, but clinical evidence is still lacking to demonstrate their benefits in the treatment of PPHN. Conclusions: Despite recent technological advances and new physiopathological knowledge, mortality associated with PPHN remains at 10%. More clinical research and evidence-based experimental results are needed to prevent, treat, and reduce the morbidity/mortality associated with this neonatal syndrome.http://www.sciencedirect.com/science/article/pii/S2255553613000487Pulmonary hypertensionPulmonary vasodilatorsNitric oxide
collection DOAJ
language Portuguese
format Article
sources DOAJ
author Joaquim E.B. Cabral
Jaques Belik
spellingShingle Joaquim E.B. Cabral
Jaques Belik
Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment
Jornal de Pediatria (Versão em Português)
Pulmonary hypertension
Pulmonary vasodilators
Nitric oxide
author_facet Joaquim E.B. Cabral
Jaques Belik
author_sort Joaquim E.B. Cabral
title Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment
title_short Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment
title_full Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment
title_fullStr Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment
title_full_unstemmed Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment
title_sort persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment
publisher Elsevier
series Jornal de Pediatria (Versão em Português)
issn 2255-5536
publishDate 2013-05-01
description Objectives: Although recognized for decades, little is known about the etiology, physiopathology, and prevention of persistent pulmonary hypertension of the newborn (PPHN). and its treatment remains a major challenge for neonatologists. In this review, the clinical features and physiopathology of the syndrome will be addressed, as well as its general and specific treatments. Data source: A review was carried out in PubMed, Cochrane Library, and MRei consult databases, searching for articles related to the syndrome and published between 1995 and 2011. Data synthesis: Risk factors and the physiopathological mechanisms of the syndrome are discussed. The clinical picture depends on the different factors involved, which are probably related to the etiology and physiopathological mechanisms. In addition to the measures used to allow the decrease in pulmonary vascular resistance after birth, some cases will require pulmonary vasodilators. Although nitric oxide has proved effective, other vasodilators have been recently used, but clinical evidence is still lacking to demonstrate their benefits in the treatment of PPHN. Conclusions: Despite recent technological advances and new physiopathological knowledge, mortality associated with PPHN remains at 10%. More clinical research and evidence-based experimental results are needed to prevent, treat, and reduce the morbidity/mortality associated with this neonatal syndrome.
topic Pulmonary hypertension
Pulmonary vasodilators
Nitric oxide
url http://www.sciencedirect.com/science/article/pii/S2255553613000487
work_keys_str_mv AT joaquimebcabral persistentpulmonaryhypertensionofthenewbornrecentadvancesinpathophysiologyandtreatment
AT jaquesbelik persistentpulmonaryhypertensionofthenewbornrecentadvancesinpathophysiologyandtreatment
_version_ 1725456809701933056